A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Active:	Yes
Cancer Type:	Multiple Myeloma Plasma cell neoplasm	NCT ID:	NCT03901963
Trial Phases:	Phase III	Protocol IDs:	CR108599 (primary) NCI-2019-03470 54767414MMY3021
Eligibility:	18 - 79 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Janssen Research & Development, LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT03901963

Summary

The purpose of this study is to evaluate conversion rate to minimal residual disease
(MRD) negativity following the addition of daratumumab to lenalidomide relative to
lenalidomide alone, when administered as maintenance treatment to anti-cluster of
differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple
myeloma who are MRD positive as determined by next generation sequencing (NGS) at
screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.